{"id":63198,"date":"2026-04-15T20:24:47","date_gmt":"2026-04-15T12:24:47","guid":{"rendered":"https:\/\/flcube.com\/?p=63198"},"modified":"2026-04-15T20:24:48","modified_gmt":"2026-04-15T12:24:48","slug":"fda-issues-draft-guidance-for-genome-editing-therapy-safety-assessment-using-next-generation-sequencing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63198","title":{"rendered":"FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing"},"content":{"rendered":"\n<p>The <strong>U.S. Food and Drug Administration (FDA)<\/strong> released draft guidance on Monday outlining standardized methods for assessing the safety of <strong>human gene therapy products<\/strong> involving <strong>genome editing technologies<\/strong>, with a specific focus on <strong>next-generation sequencing (NGS)<\/strong> methodologies to evaluate potential safety risks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-framework-overview\">Regulatory Framework Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Document Type<\/strong><\/td><td>Draft Guidance<\/td><\/tr><tr><td><strong>Title<\/strong><\/td><td>&#8220;Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing&#8221;<\/td><\/tr><tr><td><strong>Release Date<\/strong><\/td><td>14 Apr 2026<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Open for public comment before finalization<\/td><\/tr><tr><td><strong>Related Guidance<\/strong><\/td><td>Builds upon January 2024 guidance on human gene therapy products incorporating genome editing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-recommendations\">Key Recommendations<\/h2>\n\n\n\n<p>The draft guidance provides specific recommendations across four critical domains:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sequencing Strategies<\/strong>: Standardized NGS approaches to detect off-target effects<\/li>\n\n\n\n<li><strong>Sample Selection<\/strong>: Protocols for representative biological samples<\/li>\n\n\n\n<li><strong>Analysis Parameters<\/strong>: Computational methods for data interpretation<\/li>\n\n\n\n<li><strong>Reporting Requirements<\/strong>: Standardized format for submission to regulatory authorities<\/li>\n<\/ul>\n\n\n\n<p>The framework specifically addresses two primary safety concerns:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Off-target editing effects<\/strong><\/li>\n\n\n\n<li><strong>Loss of genome integrity<\/strong><\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scope-of-application\">Scope of Application<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product Type<\/th><th>Description<\/th><th>Coverage<\/th><\/tr><\/thead><tbody><tr><td><strong>Ex Vivo Products<\/strong><\/td><td>Cells edited outside the body before reintroduction to patient<\/td><td>\u2713 Included<\/td><\/tr><tr><td><strong>In Vivo Products<\/strong><\/td><td>Gene editing occurs directly within patient&#8217;s tissues<\/td><td>\u2713 Included<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The recommendations are designed to support nonclinical studies submitted with <strong>investigational new drug (IND) applications<\/strong> and <strong>Biologics License Applications (BLAs)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Pathways<\/strong>: Standardized safety assessment methods could reduce development timelines by eliminating redundant testing approaches<\/li>\n\n\n\n<li><strong>Investor Confidence<\/strong>: Clear regulatory expectations may increase investment in genome editing therapeutics<\/li>\n\n\n\n<li><strong>Global Harmonization<\/strong>: Framework aligns with emerging international standards for gene therapy evaluation<\/li>\n\n\n\n<li><strong>Early Engagement<\/strong>: FDA encourages sponsors to utilize <strong>INTERACT meetings<\/strong> and <strong>pre-IND consultations<\/strong> to discuss development strategies before formal submissions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-outlook\">Industry Outlook<\/h2>\n\n\n\n<p>The draft guidance represents a significant step toward establishing clear regulatory pathways for innovative genome editing therapies while maintaining rigorous safety standards. Companies developing CRISPR-based and other genome editing platforms will need to adapt their preclinical testing strategies to align with these recommendations.<\/p>\n\n\n\n<p>The FDA anticipates that standardized NGS-based assessment methods will ultimately bring effective treatments to patients sooner by creating more predictable regulatory review processes.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory developments and industry implications. Actual implementation timelines and impacts may vary based on public feedback, final guidance parameters, and evolving scientific understanding of genome editing technologies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) released draft guidance on Monday outlining standardized methods&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[66],"class_list":["post-63198","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-gene-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) released draft guidance on Monday outlining standardized methods for assessing the safety of human gene therapy products involving genome editing technologies, with a specific focus on next-generation sequencing (NGS) methodologies to evaluate potential safety risks.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63198\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) released draft guidance on Monday outlining standardized methods for assessing the safety of human gene therapy products involving genome editing technologies, with a specific focus on next-generation sequencing (NGS) methodologies to evaluate potential safety risks.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63198\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T12:24:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T12:24:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63198#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63198\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing\",\"datePublished\":\"2026-04-15T12:24:47+00:00\",\"dateModified\":\"2026-04-15T12:24:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63198\"},\"wordCount\":389,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gene therapy\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63198#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63198\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63198\",\"name\":\"FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-15T12:24:47+00:00\",\"dateModified\":\"2026-04-15T12:24:48+00:00\",\"description\":\"The U.S. Food and Drug Administration (FDA) released draft guidance on Monday outlining standardized methods for assessing the safety of human gene therapy products involving genome editing technologies, with a specific focus on next-generation sequencing (NGS) methodologies to evaluate potential safety risks.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63198#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63198\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63198#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Food and Drug Administration (FDA) released draft guidance on Monday outlining standardized methods for assessing the safety of human gene therapy products involving genome editing technologies, with a specific focus on next-generation sequencing (NGS) methodologies to evaluate potential safety risks.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63198","og_locale":"en_US","og_type":"article","og_title":"FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing","og_description":"The U.S. Food and Drug Administration (FDA) released draft guidance on Monday outlining standardized methods for assessing the safety of human gene therapy products involving genome editing technologies, with a specific focus on next-generation sequencing (NGS) methodologies to evaluate potential safety risks.","og_url":"https:\/\/flcube.com\/?p=63198","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-15T12:24:47+00:00","article_modified_time":"2026-04-15T12:24:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63198#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63198"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing","datePublished":"2026-04-15T12:24:47+00:00","dateModified":"2026-04-15T12:24:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63198"},"wordCount":389,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gene therapy"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63198#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63198","url":"https:\/\/flcube.com\/?p=63198","name":"FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-15T12:24:47+00:00","dateModified":"2026-04-15T12:24:48+00:00","description":"The U.S. Food and Drug Administration (FDA) released draft guidance on Monday outlining standardized methods for assessing the safety of human gene therapy products involving genome editing technologies, with a specific focus on next-generation sequencing (NGS) methodologies to evaluate potential safety risks.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63198#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63198"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63198#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63198"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63198\/revisions"}],"predecessor-version":[{"id":63199,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63198\/revisions\/63199"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}